Circulating levels of soluble angiogenic factors in multiple myeloma: Correlation with parameters of disease activity and prognosis

Current Angiogenesis

Volumn 2, Issue 2, 2013, Pages 76-95

  Alexandrakis, Michael G ^a   Tsirakis, George ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Angiogenesis; Bone marrow; Chemokines; Cytokines; Microvascular density; Multiple myeloma; Prognosis

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; B CELL ACTIVATING FACTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; COLLAGEN; ENDOGLIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; KI 67 ANTIGEN; OSTEOPONTIN; PLASMINOGEN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AB; SCATTER FACTOR; SOMATOMEDIN C; STRUCTURAL PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HUMAN; IMMUNOGLOBULIN PRODUCTION; LIVER CELL; LYMPHADENOPATHY; MULTIPLE MYELOMA; MYELOMA CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOCLAST; PERICYTE; PRIORITY JOURNAL; STROMA CELL; TUMOR VASCULARIZATION; UPREGULATION; VASCULAR TUMOR;

EID: 84952991720     PISSN: 22115528     EISSN: 22115536     Source Type: Journal    
DOI: 10.2174/22115528113026660012     Document Type: Article

References (277)

1. Giuliani N, Storti P, Bolzoni M, et al. Angiogenesis and multiple myeloma. Cancer Microenviron 2011; 4: 325-37.
2. Otjacques E, Binsfeld M, Noel A, et al. Biological aspects of angiogenesis in multiple myeloma. Int J Hematol 2011; 94: 505-18.
3. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011; 6: 249-74.
4. Ria R, Reale A, De Luisi A, et al. Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res 2011; 1: 76-89.
5. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995; 11: 73-91.
6. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
8. Ribatti D, Nico B, Crivellato E, et al. The history of the angiogenic switch concept. Leukemia 2007; 21: 44-52.
9. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
10. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210-6.
11. Kumar S, Witzig TE, Dispenzieri A, et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 2004; 18: 624-7.
12. Kumar S, Fonseca R, Dispenzieri A, et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 2002; 119: 665-71.
13. Sezer O, Niemöller K, Kaufmann O, et al. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol 2001; 66: 238-44.
14. Tsirakis G, Pappa CA, Spanoudakis M, et al. Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma. Eur J Intern Med 2012; 23: 368-73.
15. Kumar S, Rajkumar SV, Greipp PR, Witzig TE. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. Am J Hematol 2004; 77: 7-11.
16. Alexandrakis MG, Passam FH, Dambaki C, et al. The relation between bone marrow angiogenesis and the proliferation index Ki- 67 in multiple myeloma. J Clin Pathol 2004; 57: 856-60.
17. Tsirakis G, Pappa CA, Kanellou P, et al. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma. Hematol Oncol 2012; 30: 131-6.
18. Moulopoulos LA, Dimopoulos MA, Christoulas D, et al. Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia 2010; 24: 1206-12.
19. Sezer O, Niemöller K, Jakob C, et al. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2- microglobulin levels in patients with multiple myeloma. Ann Hematol 2001; 80: 598-601.
20. Pruneri G, Ponzoni M, Ferreri AJ, et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 2002; 118: 817-20.
21. Alexandrakis MG, Passam FJ, Ganotakis E, et al. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clin Chem Lab Med 2004; 42: 1122-6.
22. Kumar S, Gertz MA, Dispenzieri A, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004; 34: 235-9.
23. Alexandrakis MG, Passam FH, Pappa CA, et al. Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: its relationship to bone marrow microvessel density and other factors of disease activity. Int J Immunopathol Pharmacol 2004; 17: 49-56.
24. Bhatti SS, Kumar L, Dinda AK, Dawar R. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Am J Hematol 2006; 81: 649-56.
25. Hillengass J, Wasser K, Delorme S, et al. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res 2007; 13: 475-81.
26. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001; 28: 565-9.
27. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23; 3412-20.
28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
29. Benelli R, Lorusso G, Albini A, Noonan DM. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 2006; 12: 3101-15.
30. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
31. Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol 2012; 2012: 281261.
32. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
33. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
34. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996; 69: 135-74.
35. Kirsch M, Schackert G, Black PM. Metastasis and angiogenesis. Cancer Treat Res 2004; 117: 285-304.
36. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505-15.
37. Nishida N, Yano H, Nishida T, et al. Angiogenesis in cancer. Vasc Health Risk Manag 2006; 2: 213-9.
38. Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38: 904-10.
39. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer. 2003; 97: 2440-52.
40. DuVillard L, Guiguet M, Casasnovas RO, et al. Diagnostic value of serum IL-6 level in monoclonal gammopathies. Br J Haematol 1995; 89: 243-9.
41. Robak E, Sysa-Jedrzejowska A, Stepień H, Robak T. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur Cytokine Netw 1997; 8: 281-6.
42. Ara T, Song L, Shimada H, et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009; 69: 329-37.
43. Passam FH, Sfiridaki A, Pappa C, et al. Angiogenesis-related growth factors and cytokines in the serum of patients with B non- Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Lab Hematol 2008; 30: 17-25.
44. Passam FH, Alexandrakis MG, Moschandrea J, et al. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. Int J Immunopathol Pharmacol 2006; 19: 161-70.
45. Xirouchaki N, Tzanakis N, Bouros D, et al. Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions. Chest 2002; 121: 815-20.
46. Alexandrakis MG, Passam FH, Perisinakis K, et al. Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med 2002; 96: 553-8.
47. Alexandrakis MG, Passam FH, Kyriakou DS, Dambaki K, Niniraki M, Stathopoulos E. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol 2004; 27: 8-13.
48. Kim SY, Min HJ, Park HK, et al. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 810-20.
49. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80: 227-36.
50. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009; 374: 324-39.
51. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromalderived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17: 1175-82.
52. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41: 2502-12.
53. Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990; 87: 3092-6.
54. Dankbar B, Padró T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-6.
55. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005; 65: 10794-800.
56. Fan Y, Ye J, Shen F, et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008; 28: 90-8.
57. Alexandrakis MG, Passam FH, Boula A, et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003; 82: 19-23.
58. De Raeve H, Van Marck E, Van Camp B, Vanderkerken K. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol Histopathol 2004; 19: 935-50.
59. Brown CO, Salem K, Wagner BA, et al. Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase. Biochem J 2012; 444: 515-27.
60. Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-98.
61. Nachbaur DM, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 1991; 62: 54-8.
62. D'Auria L, Bonifati C, Mussi A, et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997; 8: 383-7.
63. Yamamura M, Yamada Y, Momita S, et al. Circulating interleukin- 6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol 1998; 100: 129-34.
64. Angstwurm MW, Gärtner R, Ziegler-Heitbrock HW. Cyclic plasma IL-6 levels during normal menstrual cycle. Cytokine 1997; 9: 370-4.
65. Mouawad R, Benhammouda A, Rixe O, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 1996; 2: 1405-9.
66. Sakamoto K, Arakawa H, Mita S, et al. Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. Cytokine 1994; 6: 181-6.
67. Ohtani K, Ninomiya H, Hasegawa Y, et al. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Br J Haematol 1995; 91: 116-20.
68. Kyrtsonis MC, Dedoussis G, Zervas C, et al. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol 1996; 93: 398-400.
69. Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101: 2775-83.
70. Stasi R, Brunetti M, Parma A, et al. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 1998; 82: 1860-6.
71. Fragioudaki M, Boula A, Tsirakis G, et al. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann Hematol 2012; 91: 1413-8.
72. Tsirakis G, Pappa CA, Kaparou M, et al. Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients. Eur J Histochem 2011; 55(3): e21.
73. Pappa CA, Tsirakis G, Samiotakis P, et al. Serum levels of angiopoietin- 2 are associated with the growth of multiple myeloma. Cancer Invest 2013; 31: 385-9.
74. Thaler J, Fechner F, Herold M, Huber H. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index. Leuk Lymphoma 1994; 12: 265-71.
75. Bataille R, Boccadoro M, Klein B, et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-7.
76. Alexandrakis MG, Passam FH, Ganotakis ES, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 2003; 25: 41-6.
77. Yang J, Wezeman M, Zhang X, et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 2007; 12: 252-65.
78. Andersen NF, Standal T, Nielsen JL, et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005; 128: 210-7.
79. Sfiridaki A, Miyakis S, Tsirakis G, et al. Systemic levels of interleukin- 6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clin Chem Lab Med 2005; 43: 934-8.
80. Pulkki K, Pelliniemi TT, Rajamäki A, et al. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 1996; 92: 370-4.
81. Hatjiharissi E, Terpos E, Papaioannou M, et al. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematol Oncol. 2004; 22: 159-68.
82. Dmoszynska A, Podhorecka M, Manko J, et al. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. Neoplasma. 2005; 52: 175-81.
83. Tsirakis G, Pappa CA, Kaparou M, et al. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines andproliferation markers in multiple myeloma. Tumour Biol 2013; 34: 859-64.
84. Rawstron AC, Fenton JA, Ashcroft J, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000; 96: 3880-6.
85. Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. Int J Cancer 2009; 124: 367-75.
86. Stephens OW, Zhang Q, Qu P, et al. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 2012; 119: 503-12.
87. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
88. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
89. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
90. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 1994; 56: 423-35.
91. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
92. Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025-31.
93. Ria R, Roccaro AM, Merchionne F, et al. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 2003; 17: 1961-6.
94. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950-61.
95. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006; 25: 4257-66.
96. Podar K, Anderson KC. Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle 2007; 6: 538-42.
97. Alexandrakis MG, Passam FH, Sfiridaki A, et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 2003; 72: 229-33.
98. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-6.
99. Neben K, Moehler T, Egerer G, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001; 7: 2675-81.
100. Cibeira MT, Rozman M, Segarra M, et al. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 2008; 41: 244-53.
101. Alexandrakis MG, Pappa CA, Miyakis S, et al. Serum interleukin- 17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med 2006; 17: 412-6.
102. Sfiridaki K, Pappa CA, Tsirakis G, et al. Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment. Mediators Inflamm 2011; 2011: 867576.
103. Alexandrakis MG, Passam FH, Sfiridaki A, et al. Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers 2004; 19: 52-7.
104. Rosiñol L, Cibeira MT, Segarra M, et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 2004; 26: 145-8.
105. Mileshkin L, Honemann D, Gambell P, et al. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. Haematologica 2007; 92: 1075-82.
106. Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berl) 2008; 86: 785-9.
107. Auguste P, Javerzat S, Bikfalvi A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 2003; 314: 157-66.
108. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/ fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-78.
109. Reuss B, von Bohlen and Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res 2003; 313: 139-57.
110. Su N, Du X, Chen L. FGF signaling: its role in bone development and human skeleton diseases. Front Biosci 2008; 13: 2842-65.
111. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16: 179-86.
112. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59: 115-65
113. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-95.
114. Ribatti D, Leali D, Vacca A, et al. In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J Cell Sci 1999; 112: 4213-21.
115. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase- 2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-73.
116. Colla S, Morandi F, Lazzaretti M, et al. Do human myeloma cells directly produce basic FGF? Blood 2003; 102: 3071-2.
117. Mitsiades CS, Mitsiades NS, Munshi NC, et al. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006; 42: 1564-73.
118. Dirix LY, Vermeulen PB, Pawinski A, et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76: 238-43.
119. Di Raimondo F, Azzaro MP, Palumbo G, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000; 85: 800-5.
120. Menzel T, Rahman Z, Calleja E, et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996; 87: 1056-63.
121. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 1999; 94: 3334-9.
122. Alexandrakis MG, Passam FH, Pappa CA, et al. Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density. Int J Immunopathol Pharmacol 2005; 18: 287-95.
123. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001; 66(2): 83-8.
124. Neben K, Moehler T, Egerer G, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001; 7: 2675-81.
125. Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, et al. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol 2004; 72: 252-8.
126. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-4.
127. Derksen PW, de Gorter DJ, Meijer HP, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003; 17: 764-74.
128. Vande Broek I, Leleu X, Schots R, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 2006; 91: 200-6.
129. Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 2000; 83: 1147-53.
130. Nakamura T. Structure and function of hepatocyte growth factor. Prog Growth Factor Res 1991; 3: 67-85.
131. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005; 15: 49-51.
132. Lesko E, Majka M. The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci 2008; 13: 1271-80.
133. Alexandrakis MG, Sfiridaki A, Miyakis S, et al. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta 2007; 379: 31-5.
134. Pappa CA, Tsirakis G, Kanellou P, et al. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma. Cytokine 2011; 56: 616-20.
135. Pappa CA, Tsirakis G, Psarakis FE, et al. Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma. Med Oncol 2013; 30: 363.
136. Sfiridaki A, Miyakis S, Pappa C, et al. Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. J Hematol Oncol 2011; 4: 22.
137. Seidel C, Børset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood 1998; 91: 806-12.
138. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002; 116: 796-802.
139. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94: 17-25.
140. Ko HM, Kang JH, Choi JH, et al. Platelet-activating factor induces matrix metalloproteinase-9 expression through Ca(2+)- or PI3Kdependent signaling pathway in a human vascular endothelial cell line. FEBS Lett 2005; 579: 6451-8.
141. Vande Broek I, Asosingh K, Allegaert V, et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004; 18: 976-82.
142. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996; 3: 895-904.
143. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007; 26: 717-24.
144. Van Valckenborgh E, Bakkus M, Munaut C, et al. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer 2002; 101: 512-8.
145. Kumta SM, Huang L, Cheng YY, et al. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci 2003; 73: 1427-36.
146. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase- 9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
147. Chantrain CF, Shimada H, Jodele S, et al. Stromal matrix metalloproteinase- 9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004; 64: 1675-86.
148. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003; 3: 589-601.
149. Dhodapkar MV, Kelly T, Theus A, et al. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase- 9 activity in the serum of patients with multiple myeloma. Br J Haematol 1997; 99: 368-71.
150. Rosen HN, Dresner-Pollak R, Moses AC, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54: 26-9.
151. Verstovsek S, Kantarjian H, Aguayo A, et al. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 2001; 114: 290-5.
152. Shimoyama S, Yamasaki K, Kawahara M, Kaminishi M. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin Cancer Res 1999; 5: 1125-30.
153. Hu GF, Chang SI, Riordan JF, Vallee BL. An angiogenin-binding protein from endothelial cells. Proc Natl Acad Sci USA 1991; 88: 2227-31.
154. Alexandrakis MG, Passam FH, Sfiridaki A, et al. Elevated serum angiogenin in multiple myeloma. Hematol J 2003; 4: 454-5.
155. Hu GF, Riordan JF. Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun 1993; 197: 682-7.
156. Strydom DJ. The angiogenins. Cell Mol Life Sci 1998; 54: 811-24.
157. Chopra V, Dinh TV, Hannigan EV. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 1997; 123: 167-72.
158. Miyake H, Hara I, Yamanaka K, et al. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 1999; 86: 316-24.
159. Alexandrakis MG, Passam FH, Pappa CA, et al. Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 2005; 29: 41-6.
160. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol 2007; 137: 560-8.
161. Li S, Ibaragi S, Hu GF. Angiogenin as a molecular target for the treatment of prostate cancer. Curr Cancer Ther Rev 2011; 7: 83-90.
162. Pappa C, Alexandrakis M, Boula A, et al. Emerging roles of endoglin/ CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients. Hematol Oncol 2013. doi: 10.1002/hon.2044.
163. Politou M, Naresh K, Terpos E, et al. Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta Haematol 2005; 114: 170-3.
164. Niedbala MJ, Stein M. Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells. Biomed Biochim Acta 1991; 50: 427-36.
165. Cohen T, Nahari D, Cerem LW, et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736-41.
166. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001; 66: 83-8.
167. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356-62.
168. Oh H, Takagi H, Suzuma K, et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999; 274: 15732-9.
169. Jones PF. Not just angiogenesis--wider roles for the angiopoietins. J Pathol 2003; 201: 515-27.
170. Gill KA, Brindle NP. Angiopoietin-2 stimulates migration of endothelial progenitors and their interaction with endothelium. Biochem Biophys Res Commun 2005; 336: 392-6.
171. Loges S, Heil G, Bruweleit M, et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005; 23: 1109-17.
172. Quartarone E, Alonci A, Allegra A, et al. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. Eur J Haematol 2006; 77: 480-5.
173. Vacca A, Scavelli C, Montefusco V, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005; 23: 5334-46.
174. Giuliani N, Colla S, Lazzaretti M, et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003; 102: 638-45.
175. Joshi S, Khan R, Sharma M, Kumar L, Sharma A. Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma. Clin Biochem 2011; 44: 590-5.
176. Bhaskar A, Gupta R, Vishnubhatla S, et al. Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leuk Lymphoma 2013; 54: 1473-8.
177. Terpos E, Anargyrou K, Katodritou E, et al. Circulating angiopoietin- 1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int J Cancer 2012; 130: 735-42.
178. Anargyrou K, Terpos E, Vassilakopoulos TP, et al. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica 2008; 93: 451-4.
179. Kastritis E, Roussou M, Michael M, et al. High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. Br J Haematol 2010; 150: 587-91.
180. Wiens KM, Lee HL, Shimada H, et al. Platelet-derived growth factor receptor beta is critical for zebrafish intersegmental vessel formation. PLoS One 2010; 5: e11324.
181. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-312.
182. Cao R, Bråkenhielm E, Li X, et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 2002; 16: 1575-83.
183. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007; 117: 2766-77.
184. McCarty MF, Somcio RJ, Stoeltzing O, et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007; 117: 2114-22.
185. Paulsson J, Sjöblom T, Micke P, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009; 175: 334-41.
186. Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 2007; 62: 105-18.
187. Zhang J, Cao R, Zhang Y, et al. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J 2009; 23: 153-63.
188. Kitami Y, Inui H, Uno S, Inagami T. Molecular structure and transcriptional regulation of the gene for the platelet-derived growth factor alpha receptor in cultured vascular smooth muscle cells. J Clin Invest 1995; 96: 558-67.
189. Standal T, Hjorth-Hansen H, Rasmussen T, et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 2004; 89: 174-82.
190. Tanaka Y, Abe M, Hiasa M, et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 2007; 13: 816-23.
191. Caers J, Gunthert U, De Raeve H, et al. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol 2006; 132: 469-77.
192. Liaw L, Almeida M, Hart CE, et al. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994; 74: 214-24.
193. Takahashi F, Akutagawa S, Fukumoto H, et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 2002; 98: 707-12.
194. Hirama M, Takahashi F, Takahashi K, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 2003; 198: 107-17.
195. Cackowski FC, Anderson JL, Patrene KD, et al. Osteoclasts are important for bone angiogenesis. Blood 2010; 115: 140-9.
196. Colla S, Morandi F, Lazzaretti M, et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2005; 19: 2166-76.
197. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001; 276: 44926-35.
198. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-11.
199. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62: 3417-27.
200. Saeki Y, Mima T, Ishii T, et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 2003; 123: 263-70.
201. Hotte SJ, Winquist EW, Stitt L, et al. Plasma osteopontin: associations with survival and metastasis to bone in men with hormonerefractory prostate carcinoma. Cancer 2002; 95: 506-12.
202. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol 2006; 34: 1289-95.
203. Dobreva I, Waeber G, James RW, Widmann C. Interleukin-8 secretion by fibroblasts induced by low density lipoproteins is p38 MAPK-dependent and leads to cell spreading and wound closure. J Biol Chem 2006; 281: 199-205.
204. Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 2002; 16: 267-9.
205. Benelli R, Albini A, Noonan D. Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. Chem Immunol Allergy 2003; 83: 167-81.
206. Li A, Varney ML, Valasek J, et al. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 2005; 8: 63-71.
207. Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002; 161: 125-34.
208. Vacca A, Ria R, Semeraro F, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 2003; 102: 3340-8.
209. Pellegrino A, Antonaci F, Russo F, et al. CXCR3-binding chemokines in multiple myeloma. Cancer Lett 2004; 207: 221-7.
210. Bendre MS, Margulies AG, Walser B, et al. Tumor-derived interleukin- 8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005; 65: 11001-9.
211. Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009; 23: 162-9.
212. Kline M, Donovan K, Wellik L, et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 2007; 31: 591-8.
213. Pappa CA, Tsirakis G, Boula A, et al. The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple. Pathol Oncol Res 2013; 19(3): 539-43.
214. Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E, et al. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int 2012; 32: 639-43.
215. Chen J, Petrus M, Bamford R, et al. Increased serum soluble IL-15R levels in T-cell large granular lymphocyte leukemia. Blood 2012; 119: 137-43.
216. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14-32.
217. Kuniyasu H, Oue N, Nakae D, et al. Interleukin-15 expression is associated with malignant potential in colon cancer cells. Pathobiology 2001; 69: 86-95.
218. Kuniyasu H, Yasui W, Shinohara H, et al. Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol 2000; 157: 1523-35.
219. Kuniyasu H, Ohmori H, Sasaki T, et al. Production of interleukin 15 by human colon cancer cells is associated with induction ofmucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 2003; 9: 4802-10.
220. Mengus C, Le Magnen C, Trella E, et al. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med. 2011; 9: 162.
221. Pappa C, Miyakis S, Tsirakis G, et al. Serum levels of interleukin- 15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 2007; 37: 171-5.
222. Pappa CA, Tsirakis G, Psarakis FE, et al. Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma. Med Oncol 2013; 30: 363.
223. Prabhala RH, Pelluru D, Fulciniti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115: 5385-92.
224. Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995; 155: 5483-6.
225. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-7.
226. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002; 38: 1564-79
227. Takahashi H, Numasaki M, Lotze MT, Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 2005; 98: 189-93.
228. Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004; 93: 39-43.
229. Meng XY, Zhou CH, Ma J, et al. Expression of interleukin-17 and its clinical significance in gastric cancer patients. Med Oncol 2012; 29: 3024-8.
230. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91.
231. Shen CJ, Yuan ZH, Liu YX, Hu GY. Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma. J Int Med Res 2012; 40: 556-64.
232. Dinarello CA. Interleukin-18. Methods 1999; 19: 121-32.
233. Park H, Byun D, Kim TS, et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett 2001; 79: 215-9.
234. Ye ZB, Ma T, Li H, et al. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 2007; 13: 1747-51.
235. Merendino RA, Gangemi S, Ruello A, et al. Serum levels of interleukin- 18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int J Biol Markers 2001; 16: 126-9.
236. So EY, Park HH, Lee CE. IFN-gamma and IFN-alpha posttranscriptionally down-regulate the IL-4-induced IL-4 receptor gene expression. J Immunol 2000; 165: 5472-9.
237. Cho ML, Min SY, Chang SH, et al. Transforming growth factor beta 1(TGF-beta1) down-regulates TNFalpha-induced RANTES production in rheumatoid synovial fibroblasts through NF-kappaBmediated transcriptional repression. Immunol Lett 2006; 105: 159-66.
238. Amin MA, Mansfield PJ, Pakozdi A, et al. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 2007; 56: 1787-97.
239. Kim J, Kim C, Kim TS, et al. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun 2006; 344: 1284-9.
240. Kim KE, Song H, Kim TS, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 2007; 26: 1468-76.
241. Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol 2007; 4: 329-35.
242. Alexandrakis MG, Passam FH, Sfiridaki K, et al. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk Res 2004; 28: 259-66.
243. Yamashita K, Iwasaki T, Tsujimura T, et al. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow. Oncol Rep 2002; 9: 1237-44.
244. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001; 12: 53-72.
245. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183: 1-9.
246. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem 2000; 275: 15099-105.
247. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57: 1050-93.
248. Menu E, van Valckenborgh E, van Camp B, Vanderkerken K. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 2009; 115: 49-57.
249. Asosingh K, Günthert U, Bakkus MH, et al. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res 2000; 60: 3096-104.
250. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005; 90: 706-7.
251. Chng WJ, Gualberto A, Fonseca R. IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia 2006; 20: 174-6.
252. Standal T, Borset M, Lenhoff S, et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002; 100: 3925-9.
253. Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002; 99: 4138-46.
254. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856-61.
255. Ferlin M, Noraz N, Hertogh C, et al. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000; 111: 626-34.
256. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-30.
257. Menu E, Kooijman R, Van Valckenborgh E, et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 2004; 90: 1076-83.
258. Greco C, Vitelli G, Vercillo G, et al. Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. J Exp Clin Cancer Res 2009; 28: 35.
259. Lee SD, Huang CY, Shu WT, et al. Pro-inflammatory states and IGF-I level in ischemic heart disease with low or high serum iron. Clin Chim Acta 2006; 370: 50-6.
260. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8.
261. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110: 1361-7.
262. Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996; 87: 1928-38.
263. Calabrò L, Fonsatti E, Bellomo G, et al. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol 2003; 194: 171-5.
264. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995; 121: 1845-54.
265. Oshima M, Oshima H, Taketo MM. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 1996; 179: 297-302.
266. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17: 41-58.
267. Hayashi T, Hideshima T, Nguyen AN, et al. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004; 10: 7540-6.
268. Takahashi N, Kawanishi-Tabata R, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001; 7: 524-32.
269. Adam PJ, Clesham GJ, Weissberg PL. Expression of endoglin mRNA and protein in human vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 247: 33-7.
270. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 1998; 184: 119-22.
271. Li C, Guo B, Wilson PB, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 2000; 89: 122-6.
272. Miller DW, Graulich W, Karges B, et al. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999; 81: 568-72.
273. Pérez-Gómez E, Del Castillo G, Juan Francisco S, et al. The role of the TGF-β coreceptor endoglin in cancer. Sci World J 2010; 10: 2367-84.
274. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med. 2004; 2: 18.
275. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-9.
276. Fonsatti E, Del Vecchio L, Altomonte M, et al. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001; 188: 1-7.
277. Oh HS, Choi JH, Park CK, et al. Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial. Int J Hematol 2002; 76: 465-70.